Hvivo Plc · LSE:HVO
Hvivo — Investor Day (June 2026)
49 slides from Hvivo's investor day presentation, Jun 11, 2026
Slide 1: Capital Markets Day
Capital Markets Day 11 June 2026 1
Slide 2: Agenda: Session 1
Agenda: Session 1 START SESSION SPEAKER 08:30 Welcome tea and coffee 09:00 hVIVO: A New Model for Early Drug Development • Yamin ‘Mo’ Khan (Chief Executive Officer, hVIVO) • Katsuhiro Mihara (Head of Consultancy, hVIVO) • Melanie Smyth (Senior Director Clinical Operations, hVIVO) 09:15 A Purpose -Bu
Slide 3: Agenda: Session 2
Agenda: Session 2 START SESSION SPEAKER • Keith Rubin, M.D. (Founder and CEO, ILiAD Biotechnologies) • Corrina Pavetto (ClinReg Consulting, LLC (formerly with Cidara)) Panel Discussion: The Expanding Role of Human Challenge Trials 10:55 • Diane Gbesemete (Research Fellow, Southampton University Hosp
Slide 4: A New Model for Integrated Early Drug Development
A New Model for Integrated Early Drug Development 4
Slide 5: Capital Markets Day – Key Message
Capital Markets Day – Key Message ‘hVIVO has evolved from a niche HCT provider into a differentiated, fully integrated early -stage drug development partner’ 5
Slide 6: The Investment Case, Reset
The Investment Case, Reset hVIVO is now a broader and more sustainable business with multiple revenue streams 1 2025 – a year of transformation Revenue was impacted by HCT cancellations, but we are emerging stronger 2 Diversification is delivering End -to-end development capabilities from pre -clini
Slide 7: Moving Towards a Diversified Revenue Mix
Moving Towards a Diversified Revenue Mix 2024 2025 2026 12% 13% c.15% 0% 35%-40% 7% 6% c.10% 45% 36% 81% 35%-40% 7 2024 (A), 2025 (A), 2026(F)
Slide 8: Disciplined Capital Allocation to Accelerate Growth and Diversification
Disciplined Capital Allocation to Accelerate Growth and Diversification Our Capital Allocation Priorities What We Would Look For in M&A 1. Organic investment - 1. Complementary scientific capabilities opportunities/people/capabilities 2. Therapeutic expertise / geographic reach 2. Targeted bolt -on
Slide 9: Pathway to Sustainable Growth, Profitability and Cash Generation
Pathway to Sustainable Growth, Profitability and Cash Generation Our financial ambition: return to profitable growth, expand margins & generate cash Metric FY2025 Actual FY2026 Guidance Medium -Term Targets Revenue Growth – 25.5% (transitional) High single -digit % 10– 15% CAGR Adjusted EBITDA Margi
Slide 10: Fixing the Bottlenecks in Early Clinical Development
Fixing the Bottlenecks in Early Clinical Development Faster, lower risk drug development at a significantly reduced cost 1 Why the current model underperforms 2 How hVIVO changes the model 3 What this unlocks Scientific Tech-enabled D ev elopment is slow & costly Consulting Integrated Delivery Faste
Slide 11: A Purpose-Built, Full-Service Drug Development Partner
A Purpose -Built, Full -Service Drug Development Partner Four integrated service lines hVIVO Consultancy hVIVO Clinical Trials hVIVO Human Challenge Trials hVIVO Laboratories o Non -Clinical, Clinical, CMC, PK o Phase I -II CRO Services o Phase II – III o Standalone Laboratory o Data management, Bio
Slide 12: The Four Service Lines
The Four Service Lines hVIVO Consulting hVIVO Clinical Trials Early -stage, strategic development Healthy volunteer and patient trials capability Lead generator for hVIVO Group New therapeutic area - respiratory, cardiometabolic Consulting with operational capability Post-CRS capability uplift hVIVO
Slide 13: Industry Trends Increasingly Favour Specialist Early Clinical Development Partners
Industry Trends Increasingly Favour Specialist Early Clinical Development Partners Outsourcing continues to increase Growing Demand for Early Phase CRO Services • Phase I is the most outsourced stage of development • Biotechs value proof -of-concept data (Phase II) Speed matters • Customers prioriti
Slide 14: Introducing hVIVO
Introducing hVIVO Katsuhiro Melanie Mihara Smyth Senior Director, Clinical Head of Consultancy Operations Chris Andrew Forsdyke Catchpole Head of Laboratory Services Chief Scientific Officer 14
Slide 15: hVIVO Consultancy
hVIVO Consultancy Katsuhiro Mihara, Head of Consultancy 15
Slide 16: Integrated Expertise Across the Early Development Journey
Integrated Expertise Across the Early Development Journey S upporting sponsors from candidate selection to clinical proof -of-concept CORE DISCIPLINARY ACTIVITIES Year 1 Year 2 Year 3 Year 4 Strategic Drug Development Consultancy CMC and Non -Clinical Clinical Phase I (First -in-Human) Regulatory Tr
Slide 17: How Consultancy Drives Long-Term Value Creation
How Consultancy Drives Long -Term Value Creation Earlier engagement Trusted expertise • Engages sponsors before critical development decisions are • 150+ due diligence and gap analysis projects for VC and biopharma made • 500+ PK/PD studies delivered • Influences programme strategy, study design and
Slide 18: hVIVO Clinical Trials
hVIVO Clinical Trials Melanie Smyth, Senior Director of Clinical Operations 18
Slide 19: Dedicated Highly Specialised Sites
Dedicated Highly Specialised Sites o 4 clinical research units – UK and Germany o Phase I – III Studies (including FIH) Consulting Clinical Research Unit Kiel Breda o 200+ beds Screening & Clinic Consulting Whitechapel o 98 Site employees across the 4 locations Leiden Quarantine, Labs, Clinical Cana
Slide 20: End-to-End Clinical Trial Services
End -to-End Clinical Trial Services Uniquely positioned to act as your single-source partner Clinical Conduct In-house Recruitment, Participant Management, Project Management, Laboratory Services Biometrics Documentation & Reporting Data Management, Biostatistics, Medical Protocol development Writin
Slide 21: Combined Database and Systems
Combined Database and Systems UK - learning from Germany o Introducing GP referral community and 36% networking events into the UK Healthy 370K o The sharing of specialised expertise including 64% Patient cardiometabolic and renal Germany - learning from the UK o Integration of knowledge and learnin
Slide 22: London: Diversifying into Non-Challenge Studies
London: Diversifying into Non -Challenge Studies Started o Vaccine studies in Sept o Severe asthma 2026 and beyond 2024 o Eosinophilic asthma o COPD o Older populations o T2DM o Large volume delivery (800+ o Hypertension contracted 7 Studies injections in 6 weeks) o Asthma (Phase II/III) o Longitudi
Slide 23: Germany: Leaders in Phase I/II Studies
Germany: Leaders in Phase I/II 114 Studies underway & o Cardiometabolic 2026 and beyond completed by disease hVIVO Germany o Hypertension o DDI studies since 2020 o Obesity (drug/drug interaction) o Diabetes o BE (Bio Equivalence) o Special Populations o MASLD/MASH Partnership with o Phase I & II st
Slide 24: hVIVO Laboratories
hVIVO Laboratories Chris Forsdyke, Head of Laboratories 24
Slide 25: A Growing Market for Specialist Analytical Services
A Growing Market for Specialist Analytical Services Positioned for growth in a critical market Market Drivers: hVIVO advantages and Specialist laboratory differentiators: services supporting drug development: o 9.9%* CAGR forecast annual o BSL -2 and BSL -3 growth in outsourced designed facilities o
Slide 26: Building Next Generation Analytical Capabilities
Building Next Generation Analytical Capabilities Rapid multiplexed NGS & Droplet Molecular testing RT -qPCR Bioinformatics digital PCR Whilst expanding our analytical capabilities, we deliver increased automation and throughput, whilst reducing clinical sample volumes supporting broader therapeutic
Slide 27: Driving the Next Phase of Laboratory Growth
Driving the Next Phase of Laboratory Growth Expanding our capabilities: Supporting all service lines: Investment in key molecular biology platforms: o Supporting hVIVO Phase I studies through the expansion into bioanalytical lab services o Next Generation Sequencing and bioinformatics o Droplet digi
Slide 28: hVIVO Human Challenge Trials
hVIVO Human Challenge Trials Dr Andrew Catchpole, Chief Scientific Officer 28
Slide 29: World Leader in Human Challenge Trials (HCT)
World Leader in Human Challenge Trials (HCT) An integrated model built on scale, experience and specialist Integrated HCT platform infrastructure – creating significant barriers to entry o 50 -bed individual en -suite o Internal infectious disease challenge unit experts Consultancy o Dedicated recru
Slide 30: Investment into New Challenge Models
Investment into New Challenge Models o World leading, expanding, challenge agent portfolio – 7 new agents added in past 2 years o >50% of costs covered by external funding from collaboration contracts o World’s only commercial hMPV, RSV B and influenza B challenge models Influenza Enhanced model H3,
Slide 31: HCTs Make A Difference
HCTs Make A Difference Maternal vaccination saving babies lives Pre -BLA/NDA hVIVO pioneered the RSV challenge model Pre -Submission Vaccine o Historically, RSV vaccines proved difficult to develop roll out MHRA / FDA o hVIVO’s RSV challenge model used to demonstrate Market authorisation approval wo
Slide 32: Expanding hVIVO's Respiratory Capabilities Beyond Viral Disease
Expanding hVIVO's Respiratory Capabilities Beyond Viral Disease Alex Mann, Senior Director Clinical Sciences, Respiratory Lead 32
Slide 33: hVIVO Respiratory Platform: Clinical Trial Value Creation
hVIVO Respiratory Platform: Clinical Trial Value Creation A differentiated, scalable respiratory clinical trial platform supporting sustained growth CHALLENGES FOR WHY RESPIRATORY RESPIRATORY TRIALS Large growing respiratory markets Barriers to efficient drug development aligned with hVIVO strengths
Slide 34: hVIVO Respiratory: Differentiation
hVIVO Respiratory: Differentiation Faster, predictable enrolment of high quality, well characterised engaged patients Recruitment Patient characterisation Specialist infrastructure o Dedicated recruitment engine o Expertise in precisely o Dedicated respiratory facilities o Proven delivery at speed &
Slide 35: A Repeatable Model for Respiratory Growth
A Repeatable Model for Respiratory Growth Creating a scalable platform: expansion across respiratory indications & long -term growth Expertise & Non -IMP IMP Ph 1/2/3 Challenge Infrastructure Recruitment Site & Lab Site & Lab studies >130 active Focus on repeat & long - P1/2/3 studies Asthma term cl
Slide 36: An Integrated Model for Early Phase Cardiometabolic Drug Development
An Integrated Model for Early Phase Cardiometabolic Drug Development Professor Thomas Forst, Chief Medical Officer 36
Slide 37: Prof. Dr. Thomas Forst, Chief Medical Officer
Prof. Dr. Thomas Forst, Chief Medical Officer Board certified physician for Internal Medicine, Endocrinology, Diabetes Mellitus German Diabetes Research Institute (Leibnitz Institute) at the Heinrich Heine University 1989 - 1991 Düsseldorf 1991 - 1999 Department of Internal Medicine and Endocrinolog
Slide 38: Cardiometabolic Disease - One of the Fastest-growing Areas in Drug Development
Cardiometabolic Disease - One of the Fastest -growing Areas in Drug Development Cardiovascular Disease Metabolic Syndrome • Insulin Resistance • Fatty Liver Disease Heart Failure • Lipid Disorders Orthopaedic Complications • Hypertension Cancer • Inflammation Sleep Apnoea • Diabetes Mellitus Type 2
Slide 39: Cardiometabolic Disease - One of the Fastest-growing Areas in Drug Development
Cardiometabolic Disease - One of the Fastest -growing Areas in Drug Development • More than 50% of adults projected to be overweight or obese by 2050¹ • Global obesity therapeutics market expected to exceed $ 111.7bn by 2035 • Pipeline innovation expanding beyond first -generation GLP -1 therapies •
Slide 40: Peptide and Non-peptide Polyagonists for Cardiometabolic Diseases in Late Stage Development
Peptide and Non -peptide Polyagonists for Cardiometabolic Diseases in Late Stage Development 40
Slide 41: Enteropeptides and Agonists in Clinical Development
Enteropeptides and Agonists in Clinical Development Key growth area Global obesity clinical trials market – set to reach $22B 1 by 2033 >11 injectables & >8 oral medications in pre -clinical development, due to reach the clinic within the next 2 years 41 1. 1. Grandview Research. 2. Global Data, Sep
Slide 42: hVIVO: Specialist Portfolio of Cardiometabolic Assessments
hVIVO : Specialist Portfolio of Cardiometabolic Assessments Obesity and Fatty Cardiovascular Metabolic Testing Biomarkers Tissue Assessments Assessments • FibroScan ® (Liver Fatty Tissue • Glucose Challenge Tests • Echocardiography (EF) • Glucose Metabolism / Insulin and Stiffness) (Glucose Clamps)
Slide 43: Academic Activities: Publications in the Cardiometabolic Segment
Academic Activities: Publications in the Cardiometabolic Segment 43
Slide 44: Building a Leading Position in Early Phase Cardiometabolic Development
Building a Leading Position in Early Phase Cardiometabolic Development • Expand obesity and metabolic disease expertise • Expansion to a multisite European cardiometabolic provider (Mannheim/London/Kiel) • Increase patient recruitment and cardiometabolic patient database across hVIVO sites • Broaden
Slide 45: Q&A
Q&A MAKING INNOVATION POSSIBLE Avivo
Slide 46: Final Closing
Final Closing MAKING (OVATION POSSIBLE
Slide 47: Real Life Examples of Our End-to-end Delivery
Real Life Examples of Our End -to-end Delivery Cidara : From HCT to Phase III Partnership Decoy Therapeutics: 31% Potential multi -service engagement Human Infectious disease Challenge Delivered critical data supporting anti-viral candidate hVIVO Trial programme progression Consultancy 2023 Clinical
Slide 48: The Investment Case — Six Reasons to Own hVIVO
The Investment Case — Six Reasons to Own hVIVO 1 2 2026: Diversification implemented 3 Key Differentiators Unrivalled Scientific Moat Stand-alone and integrated service Unique full -service offering across 200 - beds with in -house scientific/medical The world's leading HCT platform, offerings for e
Slide 49: Thank you
Thank you MAKING (OVATION POSSIBLE